Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rutland

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Calcified Tissue International|September 30, 2004
Paget's disease of bone in New Zealand: continued decline in disease severityH R Cundy, G Gamble, D Wattie, et al.
Calcified Tissue International|March 1, 2002
Bisphosphonate space measurement and dosage requirement for intravenous clodronate treatment of Paget's diseaseM Rutland, D Wattie, L Que, et al.
Bone|May 13, 1999
Paget's disease in New Zealand: is it changing?T Cundy, D Wattie, S Busch, et al.
Bone|January 1, 1997
Evidence for secular change in Paget's diseaseT Cundy, K McAnulty, D Wattie, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acidS Cliffe, M L Taylor, M Rutland, et al.
British Journal of Cancer|August 26, 1998
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugsC J Lash, A E Li, M Rutland, et al.
Australian and New Zealand Journal of Medicine|December 1, 1984
Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate)T R Fraser, H K Ibbertson, I M Holdaway, et al.
The Prostate|January 1, 1988
Treatment of metastatic prostate carcinoma with the depot LRH analog ZoladexI M Holdaway, H K Ibbertson, M S Croxson, et al.
Advances in Colloid and Interface Science|January 19, 2010
Mixtures of n-dodecyl-beta-D-maltoside and hexaoxyethylene dodecyl ether--surface properties, bulk properties, foam films, and foamsC Stubenrauch, P M Claesson, M Rutland, et al.
Seminars in Nuclear Medicine|May 13, 1999
Consensus report on quality control of quantitative measurements of renal function obtained from the renogram: International Consensus Committee from the Scientific Committee of Radionuclides in NephrourologyA Prigent, P Cosgriff, G F Gates, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Calcified Tissue International|September 30, 2004
Paget's disease of bone in New Zealand: continued decline in disease severityH R Cundy, G Gamble, D Wattie, et al.
Calcified Tissue International|March 1, 2002
Bisphosphonate space measurement and dosage requirement for intravenous clodronate treatment of Paget's diseaseM Rutland, D Wattie, L Que, et al.
Bone|May 13, 1999
Paget's disease in New Zealand: is it changing?T Cundy, D Wattie, S Busch, et al.
Bone|January 1, 1997
Evidence for secular change in Paget's diseaseT Cundy, K McAnulty, D Wattie, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acidS Cliffe, M L Taylor, M Rutland, et al.
British Journal of Cancer|August 26, 1998
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugsC J Lash, A E Li, M Rutland, et al.
Australian and New Zealand Journal of Medicine|December 1, 1984
Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate)T R Fraser, H K Ibbertson, I M Holdaway, et al.
The Prostate|January 1, 1988
Treatment of metastatic prostate carcinoma with the depot LRH analog ZoladexI M Holdaway, H K Ibbertson, M S Croxson, et al.
Advances in Colloid and Interface Science|January 19, 2010
Mixtures of n-dodecyl-beta-D-maltoside and hexaoxyethylene dodecyl ether--surface properties, bulk properties, foam films, and foamsC Stubenrauch, P M Claesson, M Rutland, et al.
Seminars in Nuclear Medicine|May 13, 1999
Consensus report on quality control of quantitative measurements of renal function obtained from the renogram: International Consensus Committee from the Scientific Committee of Radionuclides in NephrourologyA Prigent, P Cosgriff, G F Gates, et al.
Pageof 3